The epilepsy field offers a telling look at some of the larger trends in pharmaceutical research and development in the post-blockbuster era: specialty companies have emerged to dominate as big pharma has retreated from the difficult therapeutic space, but most discovery is coming from small companies that need to find partners to bring their innovations forward.
The advance of specialty pharmaceutical companies toward dominance in epilepsy R&D continued with the June 13 announcement of Upsher-Smith...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?